Leadless Pacemaker Selection for Symptomatic Bradycardia with Sinus Pauses
For symptomatic bradycardia caused by sinus pauses, a single-chamber ventricular (VVI) leadless pacemaker is the appropriate choice, as current leadless technology only offers ventricular pacing without atrial sensing or dual-chamber capability.
Understanding the Guideline Framework
The 2018 ACC/AHA/HRS guidelines establish that atrial-based pacing (AAI or DDD) is superior to single-chamber ventricular pacing for sinus node dysfunction (SND), primarily because it reduces atrial fibrillation incidence and avoids pacemaker syndrome 1. However, this recommendation was written for conventional transvenous systems—leadless pacemakers currently only provide VVI pacing.
When Leadless VVI Pacing Is Reasonable Despite Guidelines
The guidelines specifically state that "in symptomatic patients with SND in which frequent ventricular pacing is not expected or the patient has significant comorbidities that are otherwise likely to determine the survival and clinical outcomes, single chamber ventricular pacing is reasonable" (Class IIa recommendation) 1.
Key Clinical Scenarios for Leadless Pacemakers:
- Pause-predominant bradycardia where continuous pacing is not anticipated
- High infection risk patients where avoiding leads and pockets is critical
- Younger patients or those with limited vascular access where lead complications are particularly problematic 2, 3, 4
- Patients refusing conventional systems or with contraindications to transvenous leads
Available Leadless Technology
The Micra™ leadless pacemaker (referenced across multiple studies) provides VVI pacing with:
- Femoral vein delivery system
- Right ventricular fixation via nitinol tines
- Safety profile showing no unanticipated serious adverse device events in early trials 5
- Successful use documented specifically for sinus pauses 2, 3, 4, 6
The Micra AV version offers atrioventricular synchrony through accelerometer-based sensing of atrial mechanical activity 2, which partially addresses the limitation of pure VVI pacing, though it still lacks true atrial pacing capability.
Critical Caveats
Programming Considerations:
- Careful rate-responsive programming is essential if this feature is used 1
- Base rate should be set to minimize unnecessary ventricular pacing while preventing pauses
When NOT to Use Leadless Pacemakers:
- Patients requiring frequent ventricular pacing (>40% of the time) where AV dyssynchrony will significantly impact quality of life
- Need for cardiac resynchronization therapy 7
- Requirement for true dual-chamber pacing with atrial lead
Procedural Risks:
- Cardiac tamponade occurs in up to 2% of cases 7
- Femoral access complications are the most common adverse events 5
- Device extraction, if needed, carries 3% severe complication risk 7
Alternative: Temporizing with Theophylline
If permanent pacing can be delayed (e.g., active infection, patient hesitation), oral theophylline 200-400 mg daily can reduce sinus pause frequency and improve symptoms 1, 8. This is particularly useful when device implantation is contraindicated due to active infection 8, though permanent pacing remains superior for definitive symptom control 1.
The bottom line: Choose a VVI leadless pacemaker (Micra or Micra AV) when the benefits of avoiding leads and pockets outweigh the loss of atrial pacing, particularly in pause-predominant bradycardia where continuous pacing burden will be low.